Olaparib in the management of ovarian cancer | PGPM
PARP inhibitors: Synthetic lethality in the clinic | Science
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Olaparib
JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML
PARP inhibitor rejected by FDA Advisory Committee, then Approved for refractory patients | Cancer Biology
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
Therapeutic applications of PARP inhibitors in ovarian cancer - ScienceDirect
A decade of clinical development of PARP inhibitors in perspective - Annals of Oncology
PARP inhibitors in ovarian cancer - Cancer Treatment Reviews
PARP inhibitors in cancer treatment | OncologyPRO
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a <i>BRCA</i>1/2 Mutation. - Abstract - Europe PMC
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action | Science Translational Medicine
Role of PARP Inhibitors in BRCA-Related Malignancies
The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib - Gynecologic Oncology
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases - Berger - 2018 - British Journal of Pharmacology - Wiley Online Library
BRCA, HRR Deficiency, and PARP Inhibitors - ppt download
AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence
Cancers | Free Full-Text | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors | HTML
